AdeIJK Pump-Specific Inhibitors Effective against Multidrug Resistant Acinetobacter baumannii

Area of Science:

• Microbiology
• Pharmacology
• Medicinal Chemistry

Background:

• Multidrug-resistant *Acinetobacter baumannii* is a critical global health threat.
• Overproduction of AdeIJK and AdeABC efflux pumps drives antibiotic resistance in *A. baumannii*.
• Efflux pumps are key targets for overcoming multidrug resistance.

Purpose of the Study:

• To identify inhibitors of the *Acinetobacter baumannii* AdeIJK multidrug efflux pump.
• To develop analogs with improved specificity and reduced cytotoxicity.
• To evaluate the ability of identified compounds to potentiate antibiotic activity.

Main Methods:

• Screening of 4,6-diaminoquinoline analogs for AdeIJK inhibitory activity.
• Focused synthetic program to optimize lead compounds.
• Testing compound efficacy in potentiating antibiotic activity against susceptible and resistant *A. baumannii* strains.
• Assessment of cytotoxicity in A549 human lung epithelial cells.

Main Results:

• Identification of 4,6-diaminoquinoline analogs with significant AdeIJK efflux pump inhibitory activity.
• Several analogs demonstrated potentiation of erythromycin, tetracycline, and novobiocin against multidrug-resistant clinical isolates.
• The most effective analogs functioned at low micromolar concentrations, showed no intrinsic antibacterial activity, inhibited ethidium ion efflux, and exhibited low cytotoxicity.

Conclusions:

• Novel 4,6-diaminoquinoline analogs are promising efflux pump inhibitors for combating multidrug-resistant *Acinetobacter baumannii*.
• These compounds can restore antibiotic susceptibility in resistant strains.
• The identified analogs represent potential leads for developing new therapeutic strategies against challenging bacterial infections.